Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 203.64

+2.3%

12:39 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (11450)	11/19/1997 1:14:00 AM
From: Henry Niman	Read Replies (1) of 32384

John, LGND's first generation diabetes drug, Targretin is slated to finish Phase III for CTCL next year. Phase III for diabetes is a good question. They are finishing up a small Phase II trail for diabetes in Europe. They may be able to use the dosing data to go right into a Phase III trial in the US. If they can't, I suspect that they would move into Phase III in Europe and start at an earlier level in the US (I think that the Phase II was started in Europe because it was easier to use the safety data (Phase I for cancer) over there. I think that LGND is talking about a product in 3-5 years, which I thought was long, but LGND should really know more than I (not withstanding some other's views on the relationship between myself and LGND). I think that LLY is looking for Targretin to help their bottom line when Prozac goes off patent, which I think is 2002 or 2003.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next